Table 3.
Detailed Pathologic Analysis of the Second Cohort of Colorectal Adenocarcinoma Samples.
| Tumor Information |
MCMBP Staining |
Patient Information |
|||||
|---|---|---|---|---|---|---|---|
| Tumor ID | Tumor Type | Nuclear Intensity | Cytoplasmic Intensity | Percentage of MCMBP-Positive Cells in the Tumor | Relapse-Metastasis | Disease-Free Survival | Overall Survival |
| 1 | MD | Moderate | Light | 50% | Liver-Lung | 6 | 25 |
| 2 | WD | Moderate | Light | 50% | Lung | 14 | 29 |
| 3 | MD | Strong | Light | 70% | None | 60 | 60 |
| 4 | MD | Light | Light | > 90% | Paravesical | 56 | 60 |
| 5 | MD | Light | Light | > 90% | Lung | 20 | 27 |
| 6 | MD | Strong | Moderate | > 90% | None | – | – |
| 7 | MD | Strong | Light | 60% | None | 60 | 60 |
| 8 | WD | Strong | Moderate | 70% | None | 60 | 60 |
| 9 | WD | Moderate | Light | > 90% | None | 60 | 60 |
| 10 | MD | Light | Light | 60% | None | 60 | 60 |
| 11 | MD | Strong | Moderate | > 90% | None | 71 | 71 |
| 12 | PD | Strong | Light | > 90% | Liver-Peritoneal | 22 | 60 |
| 13 | WD | Strong | Light | > 90% | Lung–Adrenal | 42 | 60 |
| 14 | PD | Strong | Light | > 90% | None | 60 | 60 |
| 15 | MD | Light | Light | 100% | None | 60 | 60 |
| 16 | Moderate | Light | 50% | None | 60 | 60 | |
| 17 | WD | Strong | Strong | 80% | None | 60 | 60 |
| 18 | PD | Strong | Light | > 90% | Bronchus–Lymph node | 65 | 65 |
| 19 | WD | Strong | Moderate | 70% | None | 5 | 5 |
| 20 | PD | Light | Moderate | 90% | None | 60 | 60 |
| 21 | MD | Moderate | Moderate | > 90% | None | 60 | 60 |
| 22 | PD | Light | Light | > 90% | Small intestine | 16 | 16 |
| 23 | MD | Light | Light | > 90% | None | 60 | 60 |
| 24 | WD | Moderate | Light | 50% | None | 60 | 60 |
| 25 | MD | Moderate | Light | 50% | None | 60 | 60 |
| 26 | MD | Moderate | Light | 80% | None | 60 | 60 |
| 27 | MD | Moderate | Moderate | 50% | None | 60 | 60 |
| 28 | WD | Moderate | Light | 50% | None | 60 | 60 |
| 29 | MD | Strong | Strong | > 90% | Liver-Lung-Brain | 23 | 43 |
| 30 | PD | Moderate | Moderate | 70% | Liver | 5 | – |
| 31 | MD | Light | Moderate | > 90% | None | 60 | 60 |
| 32 | WD | Strong | Moderate | 80% | None | 60 | 60 |
| 33 | WD | Strong | Light | 70% | None | 60 | 60 |
| 34 | WD | Strong | Light | 70% | Liver | 30 | 30 |
| 35 | MD | Strong | Strong | > 90% | None | 60 | 60 |
| 36 | MD | Moderate | Strong | 60% | None | 60 | 60 |
| 37 | PD | Light | Strong | 80% | None | 0 | 0 |
| 38 | MD | Light | Moderate | 70% | Mesenteric-Omental | 39 | 39 |
| 39 | MD | Light | Moderate | 80% | None | 38 | 38 |
| 40 | PD | Moderate | Light | 80% | None | 60 | 60 |
| 41 | WD | Moderate | Light | 70% | Liver | 8 | 14 |
| 42 | PD | Strong | Light | 60% | Liver | 60 | 60 |
| 43 | MD | Light | Light | > 90% | None | 60 | 60 |
| 44 | MD | Moderate | Light | 60% | Peritoneal | 30 | 60 |
| 45 | MD | Moderate | Light | 60% | Liver-Lung | 14 | 27 |
| 46 | WD | Strong | Light | 60% | Local tumor recurrence | 24 | 38 |
| 47 | MD | Moderate | Light | 80% | None | 60 | 60 |
| 48 | PD | Strong | Light | > 90% | Brain | 12 | 16 |
| 49 | PD | Moderate | Moderate | 80% | None | – | – |
| 50 | MD | Light | Light | 50% | None | 60 | 60 |
| 51 | PD | Light | Moderate | > 90% | Liver | 5 | 5 |
| 52 | MD | Moderate | Light | 70% | None | 60 | 60 |
| 53 | MD | Strong | Strong | > 90% | None | 10 | 10 |
| 54 | MD | Moderate | Light | 50% | Liver-Bone | 18 | 20 |
WD, MD, and PD, well-, moderately, and poorly differentiated adenocarcinomas, respectively.
Disease-free survival and overall survival are given in months.